Published in Gene Therapy Weekly, June 3rd, 1996
There are several genetic disorders whereby low-level, long-term engraftment of gene therapy corrected stem cells could mean a cure. However, to date there have been only moderate successes in engraftment of enough modified hematopoietic progenitor cells (HPCs) to sustain a cure.
Michael Mardiney III and Harry L. Malech of the U.S. National Institutes of Health, showed that by using a progenitor enriched fraction of marrow from untreated mouse donors into congenic recipients that even very low-dose radiation conditioning of the recipient...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.